S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
Free Trial

Cellectar Biosciences (CLRB) News Today

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)
Free CLRB Stock Alerts
$3.06
+0.02 (+0.66%)
(As of 12:27 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
SourceHeadline
seekingalpha.com logoCLRB Cellectar Biosciences, Inc.
seekingalpha.com - April 19 at 6:19 AM
marketbeat.com logoCellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest Update
marketbeat.com - April 14 at 12:17 AM
MarketBeat logoCellectar Biosciences (NASDAQ:CLRB) Shares Pass Above 50 Day Moving Average of $3.73
americanbankingnews.com - April 9 at 4:40 AM
marketbeat.com logoCellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Above 50 Day Moving Average of $3.73
marketbeat.com - April 9 at 4:40 AM
markets.businessinsider.com logoBuy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid Financials
markets.businessinsider.com - March 29 at 1:15 PM
nz.finance.yahoo.com logoJeremy Renner Sweetly Hugs Daughter Ava in Rare Photo as He Celebrates His 'Number One' on Her 11th Birthday
nz.finance.yahoo.com - March 29 at 8:15 AM
finance.yahoo.com logoCellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven?
finance.yahoo.com - March 29 at 8:15 AM
finance.yahoo.com logoQ4 2023 Cellectar Biosciences Inc Earnings Call
finance.yahoo.com - March 28 at 1:50 AM
investorplace.com logoCLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023
investorplace.com - March 27 at 12:04 PM
msn.com logoCellectar Biosciences FY 2023 Earnings Preview
msn.com - March 27 at 10:49 AM
benzinga.com logoEarnings Preview For Cellectar Biosciences
benzinga.com - March 27 at 10:49 AM
globenewswire.com logoCellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
globenewswire.com - March 27 at 6:40 AM
globenewswire.com logoCellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
globenewswire.com - March 20 at 6:40 AM
globenewswire.com logoCellectar Biosciences to Present at the 36th Annual Roth Conference
globenewswire.com - March 14 at 8:52 AM
globenewswire.com logoCellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
globenewswire.com - March 4 at 6:40 AM
benzinga.com logoCellectar Biosciences Stock (NASDAQ:CLRB), Short Interest Report
benzinga.com - February 22 at 7:30 PM
money.usnews.com logoCellectar Biosciences Inc
money.usnews.com - February 15 at 3:11 PM
seekingalpha.com logoCellectar Biosciences: A Shoestring Opportunity You're About To Miss
seekingalpha.com - February 12 at 4:35 AM
finance.yahoo.com logoCellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
finance.yahoo.com - February 7 at 10:51 AM
finance.yahoo.com logoCellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
finance.yahoo.com - January 25 at 10:20 AM
investing.com logoCellectar Biosciences Inc (CLRB)
investing.com - January 23 at 3:40 PM
msn.com logoCellectar stock climbs 8% on results for CNS malignancy therapy
msn.com - January 22 at 7:13 PM
finance.yahoo.com logoCellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
finance.yahoo.com - January 22 at 8:25 AM
finance.yahoo.com logoCellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
finance.yahoo.com - January 16 at 7:45 AM
finance.yahoo.com logoCellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
finance.yahoo.com - January 12 at 7:39 AM
marketwatch.com logoCellectar Biosciences Shares Hit 52-Week High After Positive Iopofosine I Results
marketwatch.com - January 8 at 2:05 PM
msn.com logoWhy Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?
msn.com - January 8 at 2:05 PM
marketwatch.com logoCellectar Biosciences' Iopofosine I Meets Primary Endpoint in Rare Blood Cancer Study
marketwatch.com - January 8 at 9:05 AM
reuters.com logoCellectar's blood cancer therapy succeeds in trial
reuters.com - January 8 at 9:05 AM
msn.com logoCellectar Biosciences gains on pivotal data for radiotherapy
msn.com - January 8 at 9:05 AM
msn.com logoWhy Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
msn.com - January 8 at 9:05 AM
finance.yahoo.com logoCellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia
finance.yahoo.com - January 8 at 9:05 AM
finance.yahoo.com logoCellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024
finance.yahoo.com - January 3 at 10:21 AM
finance.yahoo.com logoCellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
finance.yahoo.com - December 19 at 9:24 AM
finance.yahoo.com logoCellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
finance.yahoo.com - December 12 at 9:43 AM
finance.yahoo.com logoCellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
finance.yahoo.com - December 5 at 12:05 PM
finance.yahoo.com logoHere's Why We're A Bit Worried About Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation
finance.yahoo.com - November 23 at 5:35 PM
markets.businessinsider.com logoBuy Rating on Cellectar Biosciences: Promising Clinical Study, Fast Track Designation and Strong Financial Position
markets.businessinsider.com - November 4 at 10:57 PM
finance.yahoo.com logoCellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 4 at 12:44 PM
msn.com logoCellectar Biosciences Q3 2023 Earnings Preview
msn.com - November 2 at 8:01 AM
finance.yahoo.com logoCellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
finance.yahoo.com - November 2 at 8:01 AM
finance.yahoo.com logoCellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
finance.yahoo.com - October 25 at 8:56 AM
finance.yahoo.com logoCellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023
finance.yahoo.com - October 24 at 8:56 AM
finance.yahoo.com logoCellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia
finance.yahoo.com - October 17 at 10:43 AM
seekingalpha.com logoCellectar Biosciences files to sell 34.5M shares for holders
seekingalpha.com - October 7 at 10:22 AM
marketwatch.com logoCellectar Biosciences Shares Rise 10% After Being Granted Four Patents
marketwatch.com - October 2 at 2:01 PM
finance.yahoo.com logoCellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
finance.yahoo.com - October 2 at 8:58 AM
finance.yahoo.com logoCellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia
finance.yahoo.com - September 18 at 12:11 PM
benzinga.com logoNano-Cap Medical Technology Watchlist (ORHB, BBLG, CLRB, MOVE)
benzinga.com - September 18 at 7:11 AM
benzinga.com logoCellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
benzinga.com - September 11 at 6:53 PM
Get Cellectar Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

Here’s how to start a “Weekend Side Hustle” from your sofa (Ad)

Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.

Weekend after weekend!

CLRB Media Mentions By Week

CLRB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CLRB
News Sentiment
▼
0.97

0.52
▲
Average
Medical
News Sentiment

CLRB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CLRB Articles
This Week
▼
2

1
▲
CLRB Articles
Average Week

Get Cellectar Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:CLRB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith